Navigation Links
Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
Date:6/28/2010

Collaboration is part of Aeterna Zentaris' strategy of personalized approach to treatment with AEZS 108, the Company's LHRH receptor targeted conjugate with doxorubicin, being investigated in multiple cancers

QUÉBEC CITY, June 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool. Selection for treatment with AEZS-108 is determined on the basis of LHRH receptor expression, currently measured immunohistochemically. In humans, LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate and pancreatic tumors. AEZS-108 is currently in Phase 2 trials for advanced LHRH receptor positive ovarian and endometrial cancer.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We are very pleased with the collaboration with Almac who have proven experience in the development and validation of companion diagnostic tools and potential biomarkers in cancer indications. AEZS-108 is a promising anticancer compound, as demonstrated by the positive final Phase 2 results in ovarian cancer expressing LHRH receptors, recently disclosed at the last ASCO meeting. This state of the art companion diagnostic tool will allow us to develop improved methods of selecting the most appropriate patients to be treated with AEZS-108 in order to enhance the efficiency of our clinical trials and hel
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... of sequencing technologies, and their applications. Current large ... companies developing them. Various applications of sequencing are ...
(Date:9/2/2015)... Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... technologies besides fluorescence in situ hybridization (FISH), ... Molecular cytogenetics includes application of nanobiotechnology, microarrays, ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging ... vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ... clinical decisions with simultaneous access to high precision medical images and electronic health ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that the ... Healthcare Conference on November 4,2008 at 8:40 a.m. Eastern ... New York City. Robert E. Hoffman, Arena,s Vice,President, Finance ... of the company, including its clinical development and discovery,programs., ...
... DURECT Corporation,(Nasdaq: DRRX ) announced today ... with Alpharma Ireland Limited, an affiliate of,Alpharma ... party the exclusive worldwide,rights to develop and ... cleared review under the,Hart-Scott-Rodino (HSR) Antitrust Improvements ...
... research shows that environmental gains derived from the use ... processes used to manufacture them. Research published in ... Ecology , a peer-reviewed journal owned by Yale University ... Environmental Studies, highlights the need for improved efficiency in ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference 3DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective 2DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective 3DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective 4A need for improved efficiency in nanomanufacturing 2
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... U.S. Department of Applied Neurobiology at the Walter Reed ... (AVC) have signed a Cooperative Research and Development Agreement ... brain injury (TBI). The alliance is based on ... NoNO Inc., of Toronto, Canada, and will explore the ...
... hospital superbugs can make poisons similar to those found ... scientists heard today (Monday 8 September 2008) at the ... week at Trinity College, Dublin. The toxins are ... called biofilms, which are up to a thousand times ...
... arsenic pollution have discovered a living sensor that can ... can clean up arsenic spills even in previously untreatable ... at the Society for General Microbiology,s Autumn meeting being ... Giant Mine in Canada is in the sub-arctic. It ...
Cached Biology News:Arbor Vita and WRAIR sign CRADA for traumatic brain injury collaboration 2Rattlesnake-type poisons used by superbug bacteria to beat our defenses 2Rattlesnake-type poisons used by superbug bacteria to beat our defenses 3Living sensor can warn of arsenic pollution 2
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
...
Recombinant Human PTP1B (aa 2-321), CF...
Biology Products: